Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $4.37 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2